MediciNova Statistics
Total Valuation
MediciNova has a market cap or net worth of $63.99 million. The enterprise value is $36.82 million.
| Market Cap | 63.99M |
| Enterprise Value | 36.82M |
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MediciNova has 49.22 million shares outstanding. The number of shares has increased by 0.12% in one year.
| Current Share Class | 49.22M |
| Shares Outstanding | 49.22M |
| Shares Change (YoY) | +0.12% |
| Shares Change (QoQ) | +0.22% |
| Owned by Insiders (%) | 2.97% |
| Owned by Institutions (%) | 11.01% |
| Float | 42.26M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 107.25 |
| Forward PS | 250.93 |
| PB Ratio | 1.62 |
| P/TBV Ratio | 2.56 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 61.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.09, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.09 |
| Quick Ratio | 8.91 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -26.24% and return on invested capital (ROIC) is -17.97%.
| Return on Equity (ROE) | -26.24% |
| Return on Assets (ROA) | -16.97% |
| Return on Invested Capital (ROIC) | -17.97% |
| Return on Capital Employed (ROCE) | -32.61% |
| Weighted Average Cost of Capital (WACC) | 7.63% |
| Revenue Per Employee | $99,440 |
| Profits Per Employee | -$1.95M |
| Employee Count | 6 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, MediciNova has paid $5,994 in taxes.
| Income Tax | 5,994 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.78% in the last 52 weeks. The beta is 0.62, so MediciNova's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +0.78% |
| 50-Day Moving Average | 1.37 |
| 200-Day Moving Average | 1.41 |
| Relative Strength Index (RSI) | 45.25 |
| Average Volume (20 Days) | 42,353 |
Short Selling Information
The latest short interest is 172,764, so 0.35% of the outstanding shares have been sold short.
| Short Interest | 172,764 |
| Short Previous Month | 153,336 |
| Short % of Shares Out | 0.35% |
| Short % of Float | 0.41% |
| Short Ratio (days to cover) | 7.23 |
Income Statement
In the last 12 months, MediciNova had revenue of $596,641 and -$11.72 million in losses. Loss per share was -$0.24.
| Revenue | 596,641 |
| Gross Profit | 47,934 |
| Operating Income | -12.92M |
| Pretax Income | -11.71M |
| Net Income | -11.72M |
| EBITDA | -12.90M |
| EBIT | -12.92M |
| Loss Per Share | -$0.24 |
Balance Sheet
The company has $27.33 million in cash and $165,198 in debt, with a net cash position of $27.16 million or $0.55 per share.
| Cash & Cash Equivalents | 27.33M |
| Total Debt | 165,198 |
| Net Cash | 27.16M |
| Net Cash Per Share | $0.55 |
| Equity (Book Value) | 39.41M |
| Book Value Per Share | 0.80 |
| Working Capital | 25.05M |
Cash Flow
In the last 12 months, operating cash flow was -$9.50 million and capital expenditures -$13,724, giving a free cash flow of -$9.51 million.
| Operating Cash Flow | -9.50M |
| Capital Expenditures | -13,724 |
| Depreciation & Amortization | 19,182 |
| Net Borrowing | n/a |
| Free Cash Flow | -9.51M |
| FCF Per Share | -$0.19 |
Margins
| Gross Margin | 8.03% |
| Operating Margin | -2,164.84% |
| Pretax Margin | -1,963.34% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MediciNova does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.12% |
| Shareholder Yield | -0.12% |
| Earnings Yield | -18.32% |
| FCF Yield | -14.86% |
Analyst Forecast
The average price target for MediciNova is $9.00, which is 592.31% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.00 |
| Price Target Difference | 592.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 370.58% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MediciNova has an Altman Z-Score of -2.29 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.29 |
| Piotroski F-Score | 1 |